

smart medication Gene – a collaboration and documentation tool for the patient journey according to hub & spoke modell in gene therapy of hemophilia A/B

A. Rösch¹, D. Schmoltdt¹

¹smart medication eHealth Solutions GmbH, Frankfurt am Main, Germany

Introduction

Since the EMA approval of gene therapy for hemophilia A and B, two new gene therapies are immediately available as treatment options. The gene therapies are characterized by a complex patient initiation and follow-up process. The smart medication GENE software platform is a collaboration and documentation tool for the entire patient journey from the initial consultations between physician and patient at the home center to the application of the gene therapy at the dosing center as well as follow-up care of the patient after therapy has been applied.

Method

smart medication Gene covers all documentation and collaboration requirements between home center and dispensing center according to the Hub & Spoke modell (see Fig. 1). The complex treatment process can be individually configured and adapted. For example, individual tasks can be assigned to the home center or the dosing center respectively. Tasks and results can be tracked, edited and marked as completed by the centers (see Fig.2). The entire patient journey is mapped: from initial discussions, patient education and proper documentation of a informed consent, outcome of the AAV test, preparation and application of gene therapy and follow-up after application of gene therapy.




Fig. 1: Requirements of the Hub & Spoke Modell




Fig. 2: Dashboard of smart medication Gene software tool to visualize the patients journey

Results

smart medication Gene was developed in close collaboration with pharmaceutical manufacturers to take into account and map all requirements for the application of gene therapy. In a further step, the software tool was extensively validated in an advisory board consisting of physicians from future home centers and dosing centers. HCPs are currently being trained in the use of smart medication Gene, so that patients can then be documented and gene therapy applied in collaboration between the centers.

Conclusion

smart medication Gene covers the entire patient journey of gene therapy in hemophilia A and B. The tool was developed in collaboration with physicians and the pharmaceutical industry for physicians. It is expected that gene therapies will be performed in Germany in a significant number after the conclusion of negotiations with the health insurance companies and that the tool smart medication Gene will be used as standard tool in Gene therapy.

